Neuropathic Pain Market Forecast: What to Expect by 2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Neuropathic Pain Market From 2025 To 2034?

The neuropathic pain market has demonstrated robust growth in recent years. It is projected to expand from $5.35 billion in 2024 to $5.78 billion in 2025, at a compound annual growth rate (CAGR) of 7.9%. The market’s historical growth can be attributed to an increasing demand for neuropathic pain drugs, the chronic pain epidemic, a growing demand for prescription treatments, and government initiatives.

The neuropathic pain market is anticipated to experience robust expansion over the coming years. Its valuation is projected to reach $7.78 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the forecast period is attributable to increasing awareness of neuropathic pain, an expanding aging population, a well-developed healthcare sector, and improved access to neuropathic pain treatments. Key trends expected over this period encompass enhanced diagnostics, progress in pain management, breakthroughs in medical research, approvals for new drugs, and various strategic initiatives.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12922&type=smp

What Are The Top Growth Drivers Impacting The Neuropathic Pain Market Outlook?

The increasing incidence of chronic pain is anticipated to stimulate the expansion of the neuropathic pain market. Chronic pain refers to persistent and continuous discomfort that extends beyond the anticipated recovery period of an injury or ailment. Its defining characteristic is its duration, typically enduring for a minimum of three to six months or longer. The escalating occurrence of chronic pain, encompassing neuropathic conditions, necessitates efficient treatments, thereby fostering research, innovation, and investment in enhanced therapies aimed at improving symptom alleviation and quality of life. For instance, in December 2023, the Scottish Health Survey 2022, released by the Scottish Government, a Scotland-based government department, indicated that in 2022, over one-third (38%) of adults in Scotland reported experiencing pain or discomfort lasting three months or more, with a greater prevalence observed among women (43%) compared to men (33%). Consequently, the rising prevalence of chronic pain is fueling the growth of the neuropathic pain market.

What Are The Major Segment Categories Driving The Neuropathic Pain Market Growth?

The neuropathic painmarket covered in this report is segmented –

1) By Treatment: Medications; Multimodal Therapy

2) By Diagnosis: Imaging; Blood Tests And Physical Examination

3) By Indication: Diabetic Neuropathy; Spinal Stenosis; Chemotherapy-Induced Peripheral Neuropathy; Other Indications

4) By End User: Hospitals; Clinics; Home Healthcare; Ambulatory Surgical Centers; Other End Users

Subsegments:

1) By Medications: Anticonvulsants; Antidepressants; Opioids; Topical Treatments; Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2) By Multimodal Therapy: Combination Of Medications; Physical Therapy; Psychological Therapy; Lifestyle Modifications; Complementary Therapies

What Long-Term Trends Will Shape The Future Growth Of The Neuropathic Pain Industry?

Leading businesses within the neuropathic pain market are incorporating AI technologies for improved diagnosis, personalized treatment regimens, continuous monitoring, drug development, and data-driven insights, all with the goal of improving patient results and optimizing pain management approaches. An example of this is seen in March 2023, when Nevro Corp., a medical device firm based in the US, introduced its Senza HFX iQ spinal cord stimulation (SCS) system. This cutting-edge system leverages artificial intelligence (AI) to provide personalized pain relief solutions for each patient. Comprising components such as the HFX iQ Implantable Pulse Generator (IPG), HFX Trial Stimulator, Charger, and HFX App, the system is engineered to address non-surgical back pain and painful diabetic neuropathy, adjusting its functionality based on patient feedback and responses. It incorporates a distinct algorithm informed by vast amounts of patient data and empowers users to modify their pain relief settings through a smartphone application. The digital infrastructure of the system supports data gathering and facilitates future software enhancements. Ultimately, this technology seeks to boost the effectiveness of pain relief by ensuring consistency and personalization, representing a notable breakthrough in SCS treatment.

Who Are The Major Companies Operating In The Neuropathic Pain Market?

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Medtronic Inc., Eli Lilly and Company, Stryker Corporation, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Boston Scientific Corporation, Biogen Inc., Zimmer Biomet Holdings Inc., Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., NuVasive Inc., Integer Holdings Corporation, Avanos Medical Inc., Orthofix Medical Inc., Nevro Corp., InvaGen Pharmaceuticals Inc., B. Braun Melsungen AG, Cirtec Medical Corp., Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, DePuy Synthes.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/neuropathic-pain-global-market-report

Which Region Shows The Highest Potential For Future Expansion In The Neuropathic Pain Market?

North America was the largest region in the neuropathic pain market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neuropathic pain market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Neuropathic Pain Market Report:

https://www.thebusinessresearchcompany.com/customise?id=12922&type=smp

Browse Through More Reports Similar to the Global Neuropathic Pain Market 2025, By The Business Research Company

Generic Central Nervous System Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/generic-central-nervous-system-drugs-global-market-report

Nerve Repair And Regenerative Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nerve-repair-and-regenerative-global-market-report

Central Nervous System Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795